多西他赛联合奈达铂治疗晚期非小细胞肺癌的临床研究

Docetaxel combined Nedaplatin in the treatment of advanced non-small cell lung cancer

目的：探讨多西他赛联合奈达铂治疗晚期非小细胞肺癌的临床疗效与毒副反应情况。方法选取32例非小细胞肺癌晚期患者,所有患者均给予75 mg/m2多西他赛联合100 mg/m2奈达铂方案治疗。每三周为一个治疗周期，治疗两个周期后观察临床疗效及毒副反应发生情况。结果32例患者治疗总有效为14/32，疾病控制率为25/32，毒副反应主要属于Ⅰ～Ⅱ度，且多项反应中以白细胞减少、恶心呕吐及脱发为主要毒副反应。结论多西他赛联合奈达铂治疗晚期非小细胞肺癌具有较高的疾病控制率，且毒副反应程度较轻，具有耐受性好的特点，可作为晚期非小细胞肺癌的首选化疗方案。

ObjectiveTo study Docetaxel combined Nedaplatin treatment of advanced non-small cell lung cancer clinical curative effect and adverse reaction.Methods32 cases of non-small cell lung cancer patients were given Docetaxel, 75 mg/m2 and Nedaplatinm, 100 mg/m2 regimen for treatment. Every three weeks for a treatment cycle, and observe the clinical curative effect and adverse reaction occurred in two cycles .ResultsThe total effective treatment of 32 patients was 14/32, disease control rates of 25/32, mainly belong to Ⅰ - Ⅱ degree of adverse reaction, and a number of the reaction with leuk openia, nausea and vomiting and hair loss as the main adverse reaction.ConclusionDocetaxel combined Nedaplatin treatment of advanced non-small cell lung cancer with high disease control rates, and the adverse reaction to a lesser degree, characterized by the good tolerance and can be used for advancing non-small cell lung cancer chemotherapy regimens as the first choice.